BPC
RNAM

Bryce Point Capital’s Avidity Biosciences RNAM Stock Holding History

Bryce Point Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,044
Closed -$408K – 401
2024
Q4 		$408K Buy
+14,044
New +$587K 0.12% 383

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryce Point Capital's RNAM Position: Q1 2025 in Review

Bryce Point Capital sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 14,044 shares — an estimated $408K sold.

Bryce Point Capital first reported a position in RNAM in Q4 2024 and held it in 1 quarter. The position peaked at $408K in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Bryce Point Capital reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 14,044 Avidity Biosciences shares in Q1 2025, an estimated $408K.
  • Bryce Point Capital first reported a position in Avidity Biosciences in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Avidity Biosciences position peaked at $408K in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.